首页> 外文期刊>Molecular medicine reports >Complete cytogenetic response to Nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: A case report
【24h】

Complete cytogenetic response to Nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: A case report

机译:慢性粒细胞白血病病例中罕见的e13a3(b2a3)BCR-ABL融合转录本对尼罗替尼的完整细胞遗传学应答:病例报告

获取原文
获取原文并翻译 | 示例
           

摘要

In the present study, an atypical case of chronic myeloid leukemia (CML) in a 32-year-old male was reported. CML cases with e13a3 breakpoint cluster region (BCR)-ABL transcripts are extremely rare. Reverse transcription quantitative-polymerase chain reaction (RT-qPCR) was initially negative due to the primer corresponding to ABL a2 sequences and diagnosis was based upon analysis of the bone marrow smear, fluorescence in situ hybridization and karyotype analysis. RT-qPCR analysis with the ABL primer, which was located in ABL exon 3 to enable the detection of fusions with either ABL a2 or exon a3 demonstrated the presence of the BCR-ABL fusion transcript e13a3. The patient responded well to Nilotinib and achieved a complete cytogenetic response after 3 months.
机译:在本研究中,报告了一名非典型病例,其中一名32岁的男性患有慢性粒细胞白血病(CML)。具有e13a3断点簇区域(BCR)-ABL转录本的CML病例极为罕见。逆转录定量聚合酶链反应(RT-qPCR)最初因与ABL a2序列相对应的引物而阴性,并且诊断是基于对骨髓涂片的分析,荧光原位杂交和核型分析。使用位于ABL外显子3中的ABL引物进行RT-qPCR分析,能够检测与ABL a2或外显子a3的融合,证明存在BCR-ABL融合转录本e13a3。该患者对尼洛替尼反应良好,并在3个月后达到了完全的细胞遗传学反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号